142 related articles for article (PubMed ID: 35320850)
41. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
[TBL] [Abstract][Full Text] [Related]
42. Salivary gland carcinomas and molecular chaos: Additional perspectives.
Sarode SC; Sarode GS; Sharma NK
Oral Oncol; 2022 Apr; 127():105802. PubMed ID: 35248923
[No Abstract] [Full Text] [Related]
43. Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome.
Xu B; Aneja A; Ghossein R; Katabi N
Hum Pathol; 2017 Sep; 67():37-44. PubMed ID: 28739497
[TBL] [Abstract][Full Text] [Related]
44. Prognostic implications of NUMB immunoreactivity in salivary gland carcinomas.
Maiorano E; Favia G; Pece S; Resta L; Maisonneuve P; Di Fiore PP; Capodiferro S; Urbani U; Viale G
Int J Immunopathol Pharmacol; 2007; 20(4):779-89. PubMed ID: 18179751
[TBL] [Abstract][Full Text] [Related]
45. Salivary gland carcinoma: Towards a more personalised approach.
Rached L; Saleh K; Casiraghi O; Even C
Cancer Treat Rev; 2024 Mar; 124():102697. PubMed ID: 38401478
[TBL] [Abstract][Full Text] [Related]
46. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
Gilbert J; Li Y; Pinto HA; Jennings T; Kies MS; Silverman P; Forastiere AA
Head Neck; 2006 Mar; 28(3):197-204. PubMed ID: 16470745
[TBL] [Abstract][Full Text] [Related]
48. A molecular guide to systemic therapy in salivary gland carcinoma.
Weaver AN; Lakritz S; Mandair D; Ulanja MB; Bowles DW
Head Neck; 2023 May; 45(5):1315-1326. PubMed ID: 36859797
[TBL] [Abstract][Full Text] [Related]
49. Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma.
Lombardi D; Tomasoni M; Lorini L; Gurizzan C; Tomasini D; Ardighieri L; Battocchio S; Bozzola A; Mattavelli D; Paderno A; Zamparini M; Farina D; Ravanelli M; Maroldi R; Maddalo M; Magrini S; Berruti A; Deganello A; Nicolai P; Bossi P; Piazza C
Oral Oncol; 2022 Mar; 126():105764. PubMed ID: 35158286
[TBL] [Abstract][Full Text] [Related]
50. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Skálová A; Stenman G; Simpson RHW; Hellquist H; Slouka D; Svoboda T; Bishop JA; Hunt JL; Nibu KI; Rinaldo A; Vander Poorten V; Devaney KO; Steiner P; Ferlito A
Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
[TBL] [Abstract][Full Text] [Related]
51. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
Bishop JA; Yonescu R; Batista D; Begum S; Eisele DW; Westra WH
Hum Pathol; 2013 Oct; 44(10):1982-8. PubMed ID: 23773480
[TBL] [Abstract][Full Text] [Related]
52. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
[TBL] [Abstract][Full Text] [Related]
53. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
54. [Metastasis of malignant tumors of the major salivary glands].
Brodskaia NIa
Stomatologiia (Mosk); 1981; 60(6):67-9. PubMed ID: 6274062
[No Abstract] [Full Text] [Related]
55. Molecular methods for detection of prognostic and predictive markers in diagnosis of adenoid cystic carcinoma of the salivary gland origin.
Šteiner P; Pavelka J; Vaneček T; Miesbauerová M; Skálová A
Cesk Patol; 2018; 54(3):132-136. PubMed ID: 30445817
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas.
Mariano FV; da Silva SD; Chulan TC; de Almeida OP; Kowalski LP
Int J Oral Maxillofac Surg; 2011 May; 40(5):504-9. PubMed ID: 21251798
[TBL] [Abstract][Full Text] [Related]
57. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Faivre S; Raymond E; Casiraghi O; Temam S; Berthaud P
J Clin Oncol; 2005 Sep; 23(25):6271-3; author reply 6273-4. PubMed ID: 16135502
[No Abstract] [Full Text] [Related]
58. Adenocarcinoma of the larynx.
Fechner RE
Can J Otolaryngol; 1975; 4(2):284-9. PubMed ID: 166743
[TBL] [Abstract][Full Text] [Related]
59. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
Meirovitz A; Shouchane-Blum K; Maly A; Bersudski E; Hirshoren N; Abrams R; Popovtzer A; Orevi M; Weinberger J
J Cancer Res Clin Oncol; 2021 May; 147(5):1335-1340. PubMed ID: 33598797
[TBL] [Abstract][Full Text] [Related]
60. Salivary gland cancers: current treatments, molecular characteristics and new therapies.
Chandana SR; Conley BA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):645-52. PubMed ID: 18402531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
